Cambrian Bio's ATX-304 demonstrated in Phase 1b trials the ability to activate AMPK, a cellular energy regulator that declines with age. Participants showed improvements in liver fat, visceral adiposity, triglycerides, and resting metabolic rate without safety concerns—validating a mechanism long pursued in longevity research.
Key Points
- ATX-304 increased resting metabolic rate by 8% in human subjects
- Liver fat and visceral adiposity declined with drug treatment
- AMPK activation restored without metabolic overstimulation or adverse events
Longevity Analysis
Metabolic decline is a core mechanism of aging that drives multiple age-related diseases. The ability to restore AMPK function addresses a fundamental dysfunction—restoring the body's capacity to manage energy allocation, fuel utilization, and cellular efficiency. This directly impacts how effectively the body generates energy, maintains structure, and defends against metabolic stress. Success in human subjects moves this from theoretical intervention to validated therapeutic pathway, shifting the focus from symptomatic treatment of obesity and diabetes to upstream restoration of metabolic health itself.
Original published by Longevity.Technology, by Kyle Umipig.